Condition: Breast Cancer · HER2-positive Breast Cancer · Sponsor: Dana-Farber Cancer Institute
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
This description comes directly from the study's public registry record.
Sara Tolaney, MD, PhD · 617-632-2335 · sara_tolaney@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Smilow Cancer Hospital Care center at Derby | Derby, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Fairfield | Fairfield, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Glastonbury | Glastonbury, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Greenwich | Greenwich, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Guilford | Guilford, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at St. Francis | Hartford, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Long Ridge | Long Ridge, Connecticut, United States | Recruiting |
| Yale Cancer Center at Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at North Haven | North Haven, Connecticut, United States | Recruiting |
| Stamford Hospital | Stamford, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care center at Torrington | Torrington, Connecticut, United States | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04893109